Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VHB937 · 2 trials · 2 indications
The CDR is a measure of cognition and function, widely used in clinical research in AD. The scale assesses six domains: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. Based on in-depth semi-structured interview, each domain is assigned a score, which is summed to obtain the Sum of Boxes (SB) score, ranging from 0 to 18 with higher scores indicating worse condition
To compare the efficacy of VHB937 vs. placebo on a composite of permanent assisted ventilation (PAV) free survival and function in DB epoch
| Arm | Type | Description |
|---|---|---|
| VHB937 Low Dose | EXPERIMENTAL | I.V. infusions |
| VHB937 High Dose | EXPERIMENTAL | I.V. infusions |
| Placebo | PLACEBO_COMPARATOR | I.V. infusions |
| Arm 1 | EXPERIMENTAL | I.V. infusions |
| Arm 2 | PLACEBO_COMPARATOR | I.V. infusions |
| Name | Type | Description |
|---|---|---|
| VHB937 | BIOLOGICAL | VHB937 solution for infusion |
| Placebo | OTHER | Solution for infusion |
Key Inclusion Criteria * Male or female participants 50 to 85 years of age * Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD * Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0 * Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging * Re...
Top 20 of 24 competitors
VHB937 is an investigational monoclonal antibody being developed for amyotrophic lateral sclerosis (ALS) and early Alzheimer's disease. It is currently in Phase 2 clinical trials for both conditions, with separate studies evaluating its effects in people with ALS and in people with early Alzheimer's disease.
VHB937 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting Phase 2 clinical trials to evaluate the drug's effects in patients with amyotrophic lateral sclerosis and early Alzheimer's disease.
VHB937 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in two separate Phase 2 trials: one for amyotrophic lateral sclerosis and one for early Alzheimer's disease.
VHB937 is being evaluated in two Phase 2 clinical trials. The first, NCT06643481, is an active but not recruiting study in 251 participants with amyotrophic lateral sclerosis across multiple countries. The second, NCT07094516, is a recruiting study in 407 participants with early Alzheimer's disease, also conducted internationally.
Yes, VHB937 is being studied in early Alzheimer's disease. The Phase 2 clinical trial NCT07094516 is currently recruiting participants aged 50 years and older with early Alzheimer's disease. The study is randomized, double-blind, and placebo-controlled, with an enrollment target of 407 participants across multiple countries.
Yes, VHB937 is being studied in amyotrophic lateral sclerosis (ALS). The Phase 2 clinical trial NCT06643481 is active but not recruiting, with 251 participants enrolled. This randomized, double-blind, placebo-controlled study is being conducted in numerous countries, including the United States, Australia, and several European and Asian nations.